Researchers at the University of California, Los Angeles, have developed a MethylScan blood test costing under $20 that analyzes cell-free DNA methylation to detect multiple cancers and liver diseases from a single sample while identifying the likely tissue of origin before symptoms appear.
A series of recent scientific developments point toward a future where routine blood tests can flag cancer, organ damage, and metabolic warning signs years before clinical symptoms manifest. From liquid biopsies capable of isolating rare tumor DNA fragments to large international hormone meta-analyses, researchers are uncovering genetic and biochemical markers that quietly signal disease long before traditional diagnostic thresholds are crossed.
MethylScan Blood Test Detects Multiple Cancers and Liver Disease for Under $20
The newly unveiled MethylScan blood test developed by researchers at the University of California, Los Angeles (UCLA) offers a novel approach to early detection. Instead of searching primarily for rare genetic mutations, the test examines DNA methylation—the chemical tags on genetic material that dictate gene activity and shift when cells become diseased.
Because an average adult human sheds 50 to 70 billion cells daily, small fragments of cell-free DNA naturally circulate in the bloodstream. However, roughly 80% to 90% of this circulating DNA originates from normal blood cells, creating an overwhelming background noise that typically drives up the cost of liquid biopsies.
To solve this hurdle, the UCLA team uses specialized enzymes to selectively cut away unmethylated DNA fragments originating from blood cells. They also deploy a genome-wide hybridization panel to enrich the remaining sample for methylated DNA from solid organs. This reduction in background noise significantly lowers sequencing needs, allowing an effective sequencing depth of 300× per sample using just 5 gigabases of data.
At a specificity rate of 98% to minimize false positives, MethylScan detected approximately 63% of cancers overall and about 55% of early-stage cancers.
“A single blood test holds the promise to detect multiple diseases across the body, including cancers and liver diseases, by sequencing cell-free DNA methylome in the blood, and it can do this with a fraction of the sequencing cost.”
Dr. Jasmine Zhou, UCLA Health Jonsson Comprehensive Cancer Center
Beyond simply flagging the presence of disease, the assay’s machine-learning algorithms distinguished between different liver diseases with approximately 85% accuracy and mapped abnormal signals back to their specific tissue of origin. The research team estimates that if sequencing costs remain below $4 per gigabase, running the test will cost less than $20 per sample.
MPN Genomic Tracking Reveal Precursor Mutations
A separate study published in Cancer Discovery tracked 30 patients with myeloproliferative neoplasms (MPNs)—a category of blood cancers affecting bone marrow. Researchers monitored patient blood and bone marrow over time to observe how genetic patterns evolved. While patients with stable disease showed little genomic shift, those whose conditions worsened accumulated harmful mutations years before routine blood work caught the progression.
Abhishek Chilkulwar, an oncologist with Orlando Health who was not involved in the MPN study, called the results a striking demonstration that a future pathological path may be written in a patient’s cells long before outward signs emerge. While the immediate clinical translation remains modest—shifting high-risk patients to more frequent blood counts and bone marrow checks rather than initiating aggressive interventions like stem cell transplants—the findings point toward future precision medicine centered on early genetic interception.
Androgens In Men Study Links Low Testosterone to Long-Term Cancer Risk
While genetic and methylation tests scan for molecular debris, broader biochemical screenings also offer a window into long-term health risks. A large international meta-analysis known as the Androgens In Men Study (AIMS), led by Professor Bu Yeap of The University of Western Australia and published in Lancet Healthy Longevity, examined data from more than 26,000 men across 11 long-running cohorts in Australia, the United States, and Europe.
The meta-analysis correlated historical blood samples with subsequent cancer outcomes over extended periods. Men whose baseline testosterone levels sat in the lowest one-fifth of the study population faced an 18% higher risk of dying from cancer compared to those in the highest one-fifth, even after adjusting for age and other health factors.
Notably, prostate cancer did not follow this pattern. Prostate cancer risk showed no relation to total testosterone levels, though it did correlate with lower levels of sex hormone-binding globulin and luteinizing hormone. Researchers emphasize that very low testosterone does not directly cause cancer or warrant automatic supplementation; instead, baseline readings below 8.6 nanomoles per liter serve as an important biomarker of diminished physical resilience or hidden metabolic stress, acting as a potential wake-up call for holistic medical checkups.
Related reading